Business Wire

Tidepool Will Integrate With Abbott’s FreeStyle Libre Portfolio for Seamless Cloud-to-Cloud Data

Tidepool collaborates with Abbott for seamless data integration with its FreeStyle Libre portfolio in the U.S., expanding patient choice and streamlining diabetes care workflows. PALO ALTO, ...
Nasdaq

New Data Show Use of Abbott's FreeStyle® Libre System Reduces All-Cause, Diabetic Ketoacidosis-Related Hospitalization Rates and Acute Diabetes Events

- Findings from the RELIEF study in France showed for the first time, in the largest retrospective analysis of its kind of nearly 75,000 people living with diabetes, use of the FreeStyle Libre system ...
Nasdaq

Real-World Data Show Abbott's FreeStyle Libre® Systems and GLP-1 Medicines Work Better Together for People with Type 2 Diabetes

Data analyses show that people with Type 2 diabetes using GLP-1 medicines saw a significant improvement in their HbA1C after adding FreeStyle Libre technology to their regimen Better HbA1c results ...
MD&M East

Abbott’s Freestyle Libre Shown to Reduce Hospitalizations for Heart Complications in Diabetic Patients

Data from Abbott’s REFLECT study show for the first time that the use of its continuous glucose monitoring technology, Freestyle Libre, can help lessen the severity of cardiovascular complications in ...
Seeking Alpha

New Study Published in The New England Journal of Medicine Demonstrates Abbott's FreeStyle Libre® 2 System Has Positive Impacts on Glucose Levels and Quality of Life

ABBOTT PARK, Ill., Oct. 6, 2022 /PRNewswire/ -- A new study published in The New England Journal of Medicine finds that for adults with Type 1 diabetes and sub-optimal glycemic control, Abbott's ...
FierceBiotech

Abbott analysis finds FreeStyle Libre CGM and GLP-1 drug adherence rise when used together

They say a rising tide lifts all boats, and that certainly seems to be the case with the new wave of drugs and devices for diabetes management. In a recent analysis (PDF), Abbott examined trends in ...
CNET

Abbott Warns Small Number of FreeStyle Libre 3 Sensors May Give Inaccurate Readings

Abbott, a leader in diabetes tech with one of the biggest lines of continuous glucose monitors, announced this week that it's issuing a voluntary medical device correction for some of its FreeStyle ...
Seeking Alpha

Abbott's FreeStyle Libre® is Named Best Medical Technology in Last 50 Years by the Galien Foundation

ABBOTT PARK, Ill., Oct. 28, 2022 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, named Abbott's FreeStyle Libre ® continuous ...
KTLA

Abbott's FreeStyle Libre® 3 Receives U.S. FDA Clearance - Features World's Smallest, Thinnest and Most Accurate 14-Day Glucose Sensor

ABBOTT PARK, Ill., May 31, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) cleared its next-generation FreeStyle Libre 3 system for use by people ...
WWLP-22News

Late-Breaking Data Demonstrate Abbott's FreeStyle Libre® 3 System is Most Accurate 14-Day Continuous Glucose Monitor

MARD is considered the simplest measurement of sensor accuracy 2 and represents the difference between a CGM system's glucose readings and a reference blood glucose measurement. The lower the MARD, ...
Business Wire

Tidepool Will Integrate With Abbott’s FreeStyle Libre Portfolio for Seamless Cloud-to-Cloud Data

PALO ALTO, Calif.--(BUSINESS WIRE)--Tidepool, a software company committed to innovations in diabetes management, is thrilled to announce a new data integration with continuous glucose monitoring (CGM ...